Latrepirdine (Dimebon TM) was originally marketed as a non-selective antihistamine in
Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer's …

Alzheimer's disease (AD) is a multifactorial neurodegenerative process whose effective
treatment will require drugs that can act simultaneously on multiple pathogenic targets …

Intracerebral and intraperitoneal inoculation with β-amyloid-rich brain extracts originating
from patients with Alzheimer's disease as well as intracerebral injection of aggregates …

Latrepirdine (Dimebon; dimebolin) is a neuroactive compound that was associated with
enhanced cognition, neuroprotection and neurogenesis in laboratory animals, and has …

Background Amyotrophic lateral sclerosis (ALS) is a disease with a strong
neuroinflammatory component sustained by activated microglia contributing to motoneuron …

Latrepirdine (Dimebon™), an anti-histamine, has shown some benefits in trials of
neurodegenerative diseases characterized by accumulation of aggregated or misfolded …

Dimebon belongs to a fast-growing group of “old” drugs that were suggested to be effective
for therapy of pathological conditions different from their original targets. Following initial …

The triggers of late-onset sporadic Alzheimer's disease (AD) are still poorly understood.
Impairment of protein phosphorylation with age is well-known; however, the role of the …

Huntington's disease is a progressive neurodegenerative disorder for which therapies are
woefully inadequate and do not prevent inevitable progression. Currently approved …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common
neurodegenerative diseases in the elderly. The key histopathological features of these …